Found: 9
Select item for more details and to access through your institution.
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2018, v. 37, n. 1, p. N.PAG, doi. 10.1186/s13046-018-0871-7
- By:
- Publication type:
- Article
Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM).
- Published in:
- PLoS ONE, 2015, v. 10, n. 3, p. 1, doi. 10.1371/journal.pone.0121071
- By:
- Publication type:
- Article
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11153-1
- By:
- Publication type:
- Article
nab -Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+).
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2020.569715
- By:
- Publication type:
- Article
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
- Published in:
- 2018
- By:
- Publication type:
- journal article
Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancer.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 19, p. 3311, doi. 10.1002/cncr.35381
- By:
- Publication type:
- Article
High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial.
- Published in:
- Contemporary Oncology / Współczesna Onkologia, 2023, v. 27, n. 4, p. 217, doi. 10.5114/wo.2023.135246
- By:
- Publication type:
- Article